Lastly, while DLS holds potential in predicting PD-L1 expression in HNSCC patients, especially in assessing the efficacy of ICI treatment, IHC testing remains the primary method for guiding clinical decision-making. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.